NASDAQ:TNDM - Tandem Diabetes Care Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$68.76 -4.80 (-6.53 %)
(As of 03/24/2019 07:55 AM ET)
Previous Close$68.76
Today's Range$68.6901 - $74.77
52-Week Range$3.90 - $74.81
Volume2.14 million shs
Average Volume3.05 million shs
Market Capitalization$3.97 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.69
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; t:slim X2 with G5 integration; and Tandem Device Updater, a PC and Mac-compatible tool that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; t:lock cartridge and infusion set products; and various pump accessories. Its products in development include automated insulin delivery systems; t:slim X2 with Basal IQ; t:slim X2 with control IQ; t:sport insulin delivery system; and connected (mobile) health mobile application. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.

Receive TNDM News and Ratings via Email

Sign-up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TNDM
CUSIPN/A
Phone858-366-6900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$183.87 million
Book Value$2.29 per share

Profitability

Net Income$-122,610,000.00

Miscellaneous

EmployeesN/A
Market Cap$3.97 billion
Next Earnings Date4/25/2019 (Estimated)
OptionableOptionable

Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?

Tandem Diabetes Care's stock reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care Inc (NASDAQ:TNDM) announced its earnings results on Tuesday, February, 26th. The medical device company reported $0.02 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.22. The medical device company earned $76.20 million during the quarter, compared to the consensus estimate of $56.34 million. Tandem Diabetes Care had a negative net margin of 66.68% and a negative return on equity of 67.92%. The firm's quarterly revenue was up 89.1% on a year-over-year basis. During the same quarter last year, the company earned ($1.23) earnings per share. View Tandem Diabetes Care's Earnings History.

When is Tandem Diabetes Care's next earnings date?

Tandem Diabetes Care is scheduled to release their next quarterly earnings announcement on Thursday, April 25th 2019. View Earnings Estimates for Tandem Diabetes Care.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care updated its FY 2019 earnings guidance on Tuesday, February, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $255-270 million, compared to the consensus revenue estimate of $219.48 million.

What price target have analysts set for TNDM?

12 Wall Street analysts have issued 12-month target prices for Tandem Diabetes Care's stock. Their forecasts range from $34.00 to $100.00. On average, they anticipate Tandem Diabetes Care's stock price to reach $61.00 in the next twelve months. This suggests that the stock has a possible downside of 11.3%. View Analyst Price Targets for Tandem Diabetes Care.

What is the consensus analysts' recommendation for Tandem Diabetes Care?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tandem Diabetes Care.

Has Tandem Diabetes Care been receiving favorable news coverage?

Media stories about TNDM stock have been trending positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tandem Diabetes Care earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned media coverage about the medical device company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near term.

Who are some of Tandem Diabetes Care's key competitors?

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), DexCom (DXCM), Square (SQ), Canopy Growth (CGC), Netflix (NFLX), Alibaba Group (BABA), Crispr Therapeutics (CRSP) and Twilio (TWLO).

Who are Tandem Diabetes Care's key executives?

Tandem Diabetes Care's management team includes the folowing people:
  • Mr. Kim D. Blickenstaff, Pres, CEO & Director (Age 67)
  • Mr. John F. Sheridan, Exec. VP & COO (Age 64)
  • Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 51)
  • Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 46)
  • Ms. Susan M. Morrison, Exec. VP & Chief Admin. Officer (Age 40)

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.32%), Lord Abbett & CO. LLC (3.16%), Frontier Capital Management Co. LLC (2.29%), Ardevora Asset Management LLP (1.92%), Eagle Asset Management Inc. (1.83%) and Orbimed Advisors LLC (1.65%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Richard P Valencia and Susan Morrison. View Institutional Ownership Trends for Tandem Diabetes Care.

Which major investors are selling Tandem Diabetes Care stock?

TNDM stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Frontier Capital Management Co. LLC, Barclays PLC, Millennium Management LLC, Two Sigma Advisers LP, Castleark Management LLC, Weiss Multi Strategy Advisers LLC and Squarepoint Ops LLC. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, David B Berger, Dick Allen, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff and Susan Morrison. View Insider Buying and Selling for Tandem Diabetes Care.

Which major investors are buying Tandem Diabetes Care stock?

TNDM stock was acquired by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Lord Abbett & CO. LLC, BlackRock Inc., Eagle Asset Management Inc., Ardevora Asset Management LLP, Orbimed Advisors LLC, Sectoral Asset Management Inc and Emerald Advisers LLC. Company insiders that have bought Tandem Diabetes Care stock in the last two years include Christopher J Twomey, Dick Allen, Kim D Blickenstaff and Richard P Valencia. View Insider Buying and Selling for Tandem Diabetes Care.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $68.76.

How big of a company is Tandem Diabetes Care?

Tandem Diabetes Care has a market capitalization of $3.97 billion and generates $183.87 million in revenue each year. The medical device company earns $-122,610,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

What is Tandem Diabetes Care's official website?

The official website for Tandem Diabetes Care is http://www.tandemdiabetes.com.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]


MarketBeat Community Rating for Tandem Diabetes Care (NASDAQ TNDM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  409 (Vote Outperform)
Underperform Votes:  405 (Vote Underperform)
Total Votes:  814
MarketBeat's community ratings are surveys of what our community members think about Tandem Diabetes Care and other stocks. Vote "Outperform" if you believe TNDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Featured Article: What are earnings reports?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel